Next Generation Armored Car T-Cell Therapy Trial Now Open

For patients with Recurrent or Refractory B-Cell malignancies, such as:

• Chronic lymphocytic lymphoma
• Transformed chronic lymphocytic lymphoma
• Diffuse large B-cell lymphoma
• High grade B-cell lymphoma
• Follicular lymphoma
• Transformed follicular lymphoma to diffuse large B-cell lymphoma
• Mantle cell lymphoma

About this Technology

“Armored” CAR T cells are a new generation of CAR T products that are being evaluated in clinical trials. This is the first trial anywhere that employs an IL-12 secreting CAR T-cell for leukemia or lymphoma. This enhanced type of immunotherapy was developed by our scientists at Roswell Park in collaboration with those at Memorial Sloan Kettering.

Current CAR T-cell therapies have been commercially available for seven years now and about 40% of patients have achieved long term remission and/or cure. With this trial we hope to see this next generation therapy benefit more patients, achieve longer remissions, and result in more cures.

Who is eligible?

Patients with refractory or recurrent B-cell malignancies that express CD-19 and have had two previous lines of therapy and have good functional status.

What your patients should know

This cutting-edge cellular therapy uses a patient’s own T cells which are engineered to combat their cancer.

• The actual delivery of the cells is a one-time infusion. However, preparation for this infusion involves several steps, including T cell collection by apheresis, lymphodepletion chemotherapy, and a x-day hospital stay.
• After T cell collection, modifying and multiplying the cells for the infusion treatment takes approximately 4-6 weeks and some patients may need bridge therapy with continued chemotherapy to control their disease during this time.
• Possible side effects include acute cytokine release syndrome. All patients are monitored closely with prompt intervention if necessary.